Navigation Links
American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
Date:7/14/2010

  • Metformin should generally be the first choice, particularly in obese patients. If it does not produce adequate HbA1c control, other medications can be considered, recognizing that knowledge is limited about the effect of other glucose-lowering agents on cardiovascular risk.
  • If a TZD (such as pioglitazone or rosiglitazone) is considered for lowering glucose, patients should not expect it to reduce the occurrence of heart attack or stroke. The rationale for choosing a TZD should be discussed with a physician. However, patients who have successfully achieved recommended HbA1c control on a TZD may consider remaining on their medication. If the treating physician and/or the patient are uncomfortable with using a TZD, another medication could be substituted.

Related links:

2010 AHA/ACC issue advisory on diabetes drugs and heart risk

http://www.newsroom.heart.org/index.php?s=43&item=970

2010 Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes,

A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation

http://circ.ahajournals.org/cgi/content/full/121/24/2694<
'/>"/>

SOURCE American Heart Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... MELVILLE, N.Y. , Nov. 21, 2014 /PRNewswire/ ... of the world,s largest health care services companies, and ... world,s largest provider of health care products and services ... announced that the companies have entered into a long-term ... service and product offerings to office-based medical practices.  This ...
(Date:11/21/2014)... research firm Kalorama information says that 2014 will be ... medical device industry.  The firm thinks the $360 billion-dollar ... growth this year, which led firms to look to ... entrance by acquisition into new competitive zones.  The company ... Global Market for Medical Devices, 5 th Edition ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... The Intellectual Property portfolio of TIGR® Matrix ... the granting of a second U.S. patent related to ... was developed based on the hypothesis that soft tissue ... mechanical load – a process known as ,mechanotransduction, which ...
... PRGO;TASE) today announced that it has received final approval ... abbreviated new drug application (ANDA) for Desloratadine tablets (5 ... upon its filing of an ANDA containing a Paragraph ... the terms of the settlement, Perrigo can commercially launch ...
Cached Medicine Technology:Novus Scientific Announces a New U.S. Patent for a Mesh Implant Comprising Two Different Resorbable Materials with Different Degradation Times and Specific Mechanical Behaviours; U.S. Patent No. -- 8,083,755 2Perrigo Announces FDA Final Approval for Desloratadine 2
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Certain genes might prevent ... to a fifth of people with type 2 diabetes, ... been pondered by doctors working with diabetic patients, one ... under the impression that exercise helps decrease insulin resistance ... Pena, director of the Center for Weight Management at ...
(Date:11/21/2014)... Richard Wolfe, co-founder and CEO of ... benefits administration strategies during the Game Changer session ... This Game Changer breakout session enables emerging providers ... solutions and best practices to top HR leaders. ... exchange between health and welfare benefits partners, HR ...
(Date:11/21/2014)... 2014 Center for Autism and Related ... Insurance Funding for Autism Workshops” to help parents of ... through the insurance coverage process. Parents will learn ... the most effective ways to access coverage. The first ... 6-8:00 p.m. at 331 Montvale Ave., 5th Floor in ...
(Date:11/21/2014)... The Ohio Children’s Trust Fund has agreed to ... of Pediatrics (Ohio AAP, [http://www.ohioaap.org ) to raise ... caregivers throughout Ohio. The new contract, which began November ... to continue the campaign that originally started in 2013. ... to continue partnering with the Ohio AAP to provide ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 The typical ... high calorie dishes, plenty of gravy and a myriad ... be the best time of year to begin losing ... Doc has uncovered the secret to losing unhealthy, embarrassing ... fattening holiday recipes. , The insight to Diet Doc’s ...
Breaking Medicine News(10 mins):Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4
... , BOTHELL, Wash., Sept. 18 ... today that on September 15, 2009, the NYSE Amex LLC ... to its previously disclosed listing deficiency as set forth in ... relates to the Company,s failure to maintain stockholder,s equity of ...
... , , , ... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of ... 57, has embarked on his third annual "Grandpa,s Road Trip" with ... the NxStage System One provides Mr. Wells the opportunity to fit ...
... , , , , ... hip abnormalities, combined with advances in diagnostic imaging techniques and minimally ... chronic, misdiagnosed hip pain. , , Increasingly, ... of degenerative hip disease, get patients back to their chosen activities ...
... , Statement of Andy Stern, President ... Andy Stern, President of the Service Employees International ... wing extremists to silence working families by attacking progressive individuals and ... moment of profound change for this country -- from kitchen tables ...
... Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: SLTM ... that it will present at the Maxim Group Growth Conference to ... New York Hotel in New York, NY. The Company,s presentation ... Stephen J. Fanning, Chairman, President and Chief Executive Officer, will ...
... CHICAGO, Sept. 18 As economic, social and political ... state,s leading provider of addiction treatment services is expanding its ... afford expensive clinics but also fail to qualify for government-funded ... a 41-year-old non-profit organization, serves more than 29,000 patients in ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 2Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 4Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 5Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2Health News:Solta Medical to Present at the Maxim Group Growth Conference 2Health News:Gateway Responding To Increased Need for Treatment Among Middle-Income Substance Abusers 2
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... catheter is specifically designed for use with ... EP deflectable NAVI-STAR catheter houses a Biosense ... indicate, in real time, exact location points ... local electrogram information. The NAVI-STAR electro-anatomical navigation ...
For Atrial Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters. The CRISTA CATH 20-pole deflectable catheter is designed for positioning along the crista terminals....
... Steerable Catheter. Steerable atrial mapping ... designs and a unique 45 ... to 24 electrodes, regular and ... active tip electrodes, and bipolar ...
Medicine Products: